Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Low Dose Rituximab for Acquired TTP
NCT01554514Phase 2Completed
- Sponsor
- Washington University School of Medicine
- Start
- Aug 2012
- Primary completion
- Feb 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab in thrombotic thrombocytopenic purpura (TTP), sponsored by Washington University School of Medicine. Started Aug 2012; status: completed.
02
Drugs
rituximab
03
Conditions
thrombotic thrombocytopenic purpura (TTP)
Beyond the preview
Go deeper on NCT01554514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01554514.